Efficacy and Tolerability of Different Starting Doses of Sorafenib in Patients With Differentiated Thyroid Cancer

BACKGROUND. Sorafenib has proven efficacy in advanced differentiated thyroid cancer (DTC), but many patients must reduce the dose or discontinue treatment because of toxicity. The tolerability and efficacy of lower starting doses of sorafenib for DTC remain largely unstudied. METHODS. We retrospecti...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Dadu, Ramona, Waguespack, Steven G., Sherman, Steven I., Hu, Mimi I., Busaidy, Naifa L., Jimenez, Camilo, Habra, Mohammed A., Ying, Anita K., Bassett, Roland L., Cabanillas, Maria E.
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2014
Assuntos:
Endocrinology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4012968/
https://ncbi.nlm.nih.gov/pubmed/24733667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0409
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares